International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates

[1]  R. Chapurlat,et al.  Are Biochemical Markers of Bone Turnover Representative of Bone Histomorphometry in 370 Postmenopausal Women? , 2015, The Journal of clinical endocrinology and metabolism.

[2]  A. Farmer,et al.  Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study , 2015, Calcified Tissue International.

[3]  R. Eastell,et al.  Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study , 2015, Osteoporosis International.

[4]  R. Eastell,et al.  Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study , 2014, Osteoporosis International.

[5]  N. Freemantle,et al.  Understanding Patients’ Adherence-Related Beliefs about Medicines Prescribed for Long-Term Conditions: A Meta-Analytic Review of the Necessity-Concerns Framework , 2013, PloS one.

[6]  M. Hiligsmann,et al.  Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group , 2013, Osteoporosis International.

[7]  S. Cummings,et al.  Treatment failure in osteoporosis , 2012, Osteoporosis International.

[8]  A. Díez-Pérez,et al.  Risk factors for prediction of inadequate response to antiresorptives , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.

[10]  C. Cooper,et al.  A reappraisal of generic bisphosphonates in osteoporosis , 2011, Osteoporosis International.

[11]  O. Mäkitie,et al.  Bone biopsy findings and correlation with clinical, radiological, and biochemical parameters in children with fractures , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  R. Eastell,et al.  Bone turnover markers and bone mineral density response with risedronate therapy: Relationship with fracture risk and patient adherence , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  C. Cooper,et al.  Partial adherence: a new perspective on health economic assessment in osteoporosis , 2011, Osteoporosis International.

[14]  C. Cooper,et al.  Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards , 2011, Osteoporosis International.

[15]  Jacques P. Brown,et al.  Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  M. Hiligsmann,et al.  Potential clinical and economic impact of nonadherence with osteoporosis medications. , 2010, Calcified tissue international.

[17]  R. Eastell,et al.  A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. , 2009, Bone.

[18]  N. Wald.  Guidance on terminology , 2008, Journal of medical screening.

[19]  P. Garnero,et al.  Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. , 2008, Clinical chemistry.

[20]  E. Badamgarav,et al.  Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. , 2007, Mayo Clinic proceedings.

[21]  Richard Eastell,et al.  Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. , 2007, The Journal of clinical endocrinology and metabolism.

[22]  J. Cramer,et al.  A systematic review of persistence and compliance with bisphosphonates for osteoporosis , 2007, Osteoporosis International.

[23]  J. Gallagher,et al.  Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. , 2005, The Journal of clinical endocrinology and metabolism.

[24]  R. Kagan,et al.  Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis , 2004, Current medical research and opinion.

[25]  N J Wald,et al.  Guidance on terminology , 2006, Journal of medical screening.

[26]  P. Delmas,et al.  Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. , 2001, Clinical chemistry.

[27]  J. Souberbielle,et al.  Differences in the Capacity of Several Biochemical Bone Markers to Assess High Bone Turnover in Early Menopause and Response to Alendronate Therapy , 2000, Osteoporosis International.

[28]  R. Eastell,et al.  Response of Biochemical Markers of Bone Turnover to Hormone Replacement Therapy: Impact of Biological Variability , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.